Lack of association between folate-receptor autoantibodies and neural-tube defects

New England Journal of Medicine

Volumn 361, Issue 2, 2009, Pages 152-160

  Molloy, Anne M ^a,b   Quadros, Edward V ^d   Sequeira, Jeffrey M ^d   Troendle, James F ^e   Scott, John M ^b   Kirke, Peadar N ^c   Mills, James L ^e  

^a TRINITY COLLEGE DUBLIN   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

^c HEALTH RESEARCH BOARD   (Ireland)

^d STATE UNIVERSITY OF NEW YORK   (United States)

^e EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; FOLATE RECEPTOR AUTOANTIBODY; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CAUSAL ATTRIBUTION; CONTROLLED STUDY; FEMALE; HUMAN; IRELAND; MAJOR CLINICAL STUDY; MALE; NEURAL TUBE DEFECT; PREGNANCY; PREGNANCY COMPLICATION; PRIORITY JOURNAL;

EID: 67650506334     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0803783     Document Type: Article

References (16)

1. Tamura T, Picciano MF. Folate and human reproduction. Am J Clin Nutr 2006;83:993-1016.
2. Rothenberg SP, da Costa MP, Sequeira JM, et al. Autoantibodies against folate receptors in women with a pregnancy complicated by a neural-tube defect. N Engl J Med 2004;350:134-42.
3. Cabrera RM, Shaw GM, Ballard JL, et al. Autoantibodies to folate receptor during pregnancy and neural tube defect risk. J Reprod Immunol 2008;79:85-92.
4. Ramaekers VT, Rothenberg SP, Sequeira JM, et al. Autoantibodies to folate receptors in the cerebral folate deficiency syndrome. N Engl J Med 2005;352:1985-91.
5. Ramaekers VT, Blau N, Sequeira JM, Nassogne MC, Quadros EV. Folate receptor autoimmunity and cerebral folate deficiency in low-functioning autism with neurological deficits. Neuropediatrics 2007; 38:276-81.
6. Ramaekers VT, Sequeira JM, Blau N, Quadros EV. A milk-free diet downregulates folate receptor autoimmunity in cerebral folate deficiency syndrome. Dev Med Child Neurol 2008;50:346-52.
7. Little J, Elwood JM. Geographical variation. In: Elwood JM, Little J, Elwood JH, eds. Epidemiology and control of neural tube defects. Monographs in epidemiology and biostatistics. Vol. 20. Oxford, England: Oxford University Press, 1992: 96-145.
8. Shields DC, Kirke PN, Mills JL, et al. The "thermolabile" variant of methylenetetrahydrofolate reductase and neural tube defects: an evaluation of genetic risk and the relative importance of the genotypes of the embryo and the mother. Am J Hum Genet 1999;64:1045-55.
9. Brody LC, Conley M, Cox C, et al. A polymorphism, R653Q, in the trifunctional enzyme methylenetetrahydrofolate dehydrogenase/ methenyltetrahydrofolate cyclohydrolase/formyltetrahydrofolate synthe tase is a maternal genetic risk factor for neural tube defects: report of the Birth Defects Research Group. Am J Hum Genet 2002;71:1207-15.
10. Molloy AM, Scott JM. Microbiological assay for serum, plasma, and red cell folate using cryopreserved, microtiter plate method. Methods Enzymol 1997;281:43-53.
11. Bliek JB, Rothenberg SP, Steegers-Theunissen RP. Maternal folate receptor autoantibodies and cleft lip and/or palate. Int J Gynaecol Obstet 2006;93:142-3.
12. Berrocal-Zaragoza MI, Fernandez-Ballart JD, Murphy MM, Cavallé-Busquets P, Sequeira JM, Quadros EV. Association between blocking folate receptor autoantibodies and subfertility. Fertil Steril 2009;91:Suppl:1518-21.
13. Da Costa M, Rothenberg SP. Appearance of a folate binder in leukocytes and serum of women who are pregnant or taking oral contraceptives. J Lab Clin Med 1974;83:207-14.
14. Kelemen LE. The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander? Int J Cancer 2006;119:243-50.
15. Elnakat H, Ratnam M. Distribution, functionality and gene regulation of folate receptor isoforms: implications in targeted therapy. Adv Drug Deliv Rev 2004;56:1067-84.
16. Knutson KL, Krco CJ, Erskine CL, et al. T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer. J Clin Oncol 2006;24:4254-61.